The mission of the ALS Therapy Development Institute (ALS TDI) is to develop effective therapeutics that slow or stop amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease) as soon as possible for patients today.
Focused on meeting this urgent unmet medical need, ALS TDI executes a robust target discovery program, while simultaneously operating the world’s largest efforts to preclinically validate potential therapeutics; including a pipeline of dozens of small molecules, protein biologics, gene therapies and cell-based constructs.
The world’s first nonprofit biotech institute, ALS TDI has developed an industrial-scale platform, employs 30 professional scientists and evaluates dozens of potential therapeutics each year. ALS TDI collaborates with leaders in both academia and industry to accelerate ALS therapeutic development, including Biogen Idec, UCB, Aestus Therapeutics, MDA and RGK Foundation.
ALS TDI is a 501©3 registered charitable nonprofit organization. For more information, please visit us online at www.als.net.
Celebrity supporters (3)
ALS Therapy Development Institute has received support from the following celebrities:
Kudos from readers for ALS Therapy Development Institute new
Be the first to give kudos to ALS Therapy Development Institute
Show your appreciation for ALS Therapy Development InstituteSign in to give kudos